DK0682529T4 - Antistof til behandling af insulinkrævende diabetes - Google Patents

Antistof til behandling af insulinkrævende diabetes

Info

Publication number
DK0682529T4
DK0682529T4 DK94909584T DK94909584T DK0682529T4 DK 0682529 T4 DK0682529 T4 DK 0682529T4 DK 94909584 T DK94909584 T DK 94909584T DK 94909584 T DK94909584 T DK 94909584T DK 0682529 T4 DK0682529 T4 DK 0682529T4
Authority
DK
Denmark
Prior art keywords
antibody
insulin
treatment
requiring diabetes
diabetes
Prior art date
Application number
DK94909584T
Other languages
Danish (da)
English (en)
Other versions
DK0682529T3 (da
Inventor
Linda C Burkly
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21848497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0682529(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK0682529T3 publication Critical patent/DK0682529T3/da
Publication of DK0682529T4 publication Critical patent/DK0682529T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK94909584T 1993-02-09 1994-02-09 Antistof til behandling af insulinkrævende diabetes DK0682529T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2933093A 1993-02-09 1993-02-09
PCT/US1994/001456 WO1994017828A2 (en) 1993-02-09 1994-02-09 Treatment for insulin dependent diabetes

Publications (2)

Publication Number Publication Date
DK0682529T3 DK0682529T3 (da) 1998-09-07
DK0682529T4 true DK0682529T4 (da) 2006-05-15

Family

ID=21848497

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94909584T DK0682529T4 (da) 1993-02-09 1994-02-09 Antistof til behandling af insulinkrævende diabetes

Country Status (13)

Country Link
US (2) US5888507A (ja)
EP (1) EP0682529B2 (ja)
JP (1) JP3593343B2 (ja)
AT (1) ATE161730T1 (ja)
AU (1) AU687790B2 (ja)
CA (1) CA2155303C (ja)
DE (1) DE69407758T3 (ja)
DK (1) DK0682529T4 (ja)
ES (1) ES2114183T5 (ja)
GR (1) GR3026531T3 (ja)
HK (1) HK1008731A1 (ja)
NZ (1) NZ262615A (ja)
WO (1) WO1994017828A2 (ja)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2148712C (en) 1992-11-13 2012-01-17 Thalia Papayannopoulou Peripheralization of hematopoietic stem cells
DE69419721T2 (de) * 1993-01-12 2000-04-27 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
AU687790B2 (en) * 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US5677291A (en) * 1993-12-10 1997-10-14 Hoechst Marion Roussel, Inc. Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
US5750336A (en) * 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5608095A (en) * 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
US5795876A (en) * 1996-04-30 1998-08-18 Hoechst Marion Rousssel, Inc. Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6114572A (en) * 1996-11-20 2000-09-05 Hoechst Marion Roussel, Inc. Substituted phenols and thiophenols useful as antioxidant agents
ES2289778T3 (es) * 1997-04-18 2008-02-01 Biogen Idec Ma Inc. Proteinas de fusion de la region constante de la inmunoglobulina/receptor tgf-beta tipo ii.
US6121463A (en) * 1997-06-24 2000-09-19 Hoechst Marion Roussel, Inc. Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
PL203114B1 (pl) 1998-09-14 2009-08-31 Regents Board Of Zastosowania przeciwciała przeciw VLA-4 lub jego fragmentu wiążącego antygen, przeciwciała przeciw integrynie alfa-4/beta7 lub jego fragmentu wiążącego antygen lub przeciwciała przeciw VCAM-1 lub jego fragmentu wiążącego antygen, zastosowania rozpuszczalnych polipeptydów VLA-4 lub VCAM-1, które antagonizują interakcję VLA-4/VCAM-1
US6110109A (en) * 1999-03-26 2000-08-29 Biosignia, Inc. System and method for predicting disease onset
IL145898A0 (en) 1999-04-22 2002-07-25 Biogen Inc Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
EA011384B1 (ru) 1999-06-01 2009-02-27 Байоджен Айдек Ма Инк. Способ лечения воспалительного заболевания
DK1214091T3 (da) * 1999-09-14 2006-08-28 Biogen Idec Inc Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister
US20010046489A1 (en) 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US20060115473A1 (en) * 2000-12-14 2006-06-01 Biogen Idec Ma Inc., A Massachusetts Corporation Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
ES2415708T3 (es) 1999-12-16 2013-07-26 Biogen Idec Ma Inc. Métodos de tratamiento de la lesión isquémica o hemorrágica del sistema nervioso central mediante el uso de antagonistas anti-integrina alfa4
JP3459609B2 (ja) * 2000-03-17 2003-10-20 三洋電機株式会社 ライトキャッシュ回路、ライトキャッシュ回路を備えた記録装置、およびライトキャッシュ方法
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
UA83791C2 (ru) 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
US7576101B2 (en) 2003-01-24 2009-08-18 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN103169965A (zh) 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
NZ556105A (en) * 2004-12-03 2009-12-24 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis
CN101351710B (zh) 2005-04-04 2013-06-05 生物基因Idecma公司 评价对治疗性蛋白质的免疫应答的方法和产品
AU2006316629A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
DK2034830T3 (da) 2006-05-25 2014-10-27 Biogen Idec Inc Anti-vla-1-antistof til behandling af slagtilfælde
MX2009013593A (es) 2007-06-14 2010-01-20 Biogen Idec Inc Formulaciones de anticuerpos.
EP2200611A4 (en) 2007-09-14 2010-09-22 Biogen Idec Inc COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE MULTIFOCAL LEUCOENCEPHALEPATHY (PML)
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
MX2011010971A (es) * 2009-04-17 2012-01-19 Biogen Idec Inc Composiciones y metodos para tratar leucemia mielogena aguda.
EP2467159A1 (en) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
EP2485762B1 (en) 2009-10-11 2017-12-13 Biogen MA Inc. Anti-vla-4 related assays
AU2011239512B2 (en) 2010-04-16 2016-01-21 Biogen Ma Inc. Anti-VLA-4 antibodies
LT3326645T (lt) 2010-10-25 2020-08-10 Biogen Ma Inc. Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai
UY34054A (es) 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US10160808B2 (en) 2012-02-16 2018-12-25 Santarus, Inc. Anti-VLA1 (CD49A) antibody pharmaceutical compositions
EP3575311A1 (en) 2012-03-20 2019-12-04 Biogen MA Inc. Jcv neutralizing antibodies
EP2845134A1 (en) 2012-04-20 2015-03-11 Biogen Idec MA Inc. Cognitive composite parameters and uses thereof for evaluating multiple sclerosis
CN104470541A (zh) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
EP2883177A1 (en) 2012-08-13 2015-06-17 Biogen Idec MA Inc. Disease progression parameters and uses thereof for evaluating multiple sclerosis
EP3750560A3 (en) 2012-10-09 2021-03-24 Biogen MA Inc. Combination therapies and uses for treatment of demyelinating disorders
WO2015063604A2 (en) 2013-11-01 2015-05-07 Imberti Luisa BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
AU2017297404A1 (en) 2016-07-13 2019-01-24 Biogen Ma Inc. Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders
WO2018045162A1 (en) 2016-09-01 2018-03-08 Biogen Ma Inc. Biomarkers predictive of primary progressive multiple sclerosis and uses thereof
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
CA3133072A1 (en) 2019-03-11 2020-09-17 Biogen Ma Inc. Pharmaceutical compositions containing anti-lingo-1 antibodies
WO2022162164A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
US5053393A (en) * 1988-07-20 1991-10-01 Monsanto Company Novel platelet-aggregation inhibitor
JPH04501565A (ja) * 1988-11-14 1992-03-19 ブリガム・アンド・ウイメンズ・ホスピタル Ｅｌａｍ―１に特異的な抗体およびその用途
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5061693A (en) * 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
IL113261A (en) † 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Repression by peptides of lymphocyte binding to vascular endothelium by interaction of extracellular uterine capacitor with connective tissue, and pharmaceutical preparations containing
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
US5053392A (en) * 1989-12-01 1991-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1993008823A1 (en) * 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
ATE150319T1 (de) * 1992-01-13 1997-04-15 Biogen Inc Behandlung von asthma
WO1993015764A1 (en) * 1992-02-12 1993-08-19 Biogen, Inc. Treatment for inflammatory bowel disease
CA2148712C (en) * 1992-11-13 2012-01-17 Thalia Papayannopoulou Peripheralization of hematopoietic stem cells
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
DE69419721T2 (de) * 1993-01-12 2000-04-27 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
AU687790B2 (en) * 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
KR100367948B1 (ko) * 1994-01-25 2003-07-12 엘란 파마슈티칼스, 인크. 백혈구부착분자vla-4에대한인체화된항체

Also Published As

Publication number Publication date
JP3593343B2 (ja) 2004-11-24
CA2155303A1 (en) 1994-08-18
AU687790B2 (en) 1998-03-05
ATE161730T1 (de) 1998-01-15
DE69407758T2 (de) 1998-08-27
CA2155303C (en) 2010-04-20
EP0682529A1 (en) 1995-11-22
WO1994017828A2 (en) 1994-08-18
NZ262615A (en) 1996-02-27
AU6237994A (en) 1994-08-29
JPH08508719A (ja) 1996-09-17
EP0682529B2 (en) 2005-12-28
HK1008731A1 (en) 1999-05-14
ES2114183T3 (es) 1998-05-16
EP0682529B1 (en) 1998-01-07
GR3026531T3 (en) 1998-07-31
DE69407758D1 (de) 1998-02-12
US5888507A (en) 1999-03-30
WO1994017828A3 (en) 1994-10-13
US20050208053A1 (en) 2005-09-22
ES2114183T5 (es) 2006-06-16
DE69407758T3 (de) 2007-05-24
DK0682529T3 (da) 1998-09-07

Similar Documents

Publication Publication Date Title
DK0682529T4 (da) Antistof til behandling af insulinkrævende diabetes
DK0626861T3 (da) Behandling af astma.
FI870217A0 (fi) Plugganordning.
EA200000748A1 (ru) Способ введения мономерных аналогов инсулина
DK0966447T3 (da) Anvendelige små molekyler til behandling af betændelsessygdomme
DE68915162D1 (de) Nadelloses einweg-injektionssystem.
DK0832097T3 (da) System og fremgangsmåde til modifikation og rensning af peptider
DK0703788T3 (da) Stabiliseret phenylalaninammoniaklyase
PT948541E (pt) Analogos da pthrp
DK0430200T3 (da) Polypeptidholdigt lægemiddel til subkutan eller intramuskulær applikation
ATE192165T1 (de) Abtrennung von polymerisiertem und unpolymerisiertem hämoglobin unter verwendung von hydroxyapatit
YU5800A (sh) Univerzalno primenljiva krvna plazma
MX9702152A (es) Clonacion de una aminopeptidasa de membrana, dependiente de la insulina, a partir de vesiculas de glut-4.
IT1279684B1 (it) Siringa per iniezioni ipodermiche.
AU548677B2 (en) Peptides derived from glucagon
DK0586589T3 (da) Amylin- eller amylinanalogpræparat, som eventuelt indeholder insulin, til behandling af anoreksi og beslægtede tilstande
DE3683332D1 (de) Cyanatabspaltung von pergolidzwischenverbindung.
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
EP0235904A3 (en) Treatment of allergy with thymopentin
PT659883E (pt) Proteina p140 e adn que a codifica
ES2102847T3 (es) Procedimiento para la preparacion de bis(2-benzoxazolil)estilbenos.
DE69805002D1 (de) Kv2.1 antagonisten
DK31589D0 (da) Assay for begyndende diabetes, monoklonale antistoffer til anvendelse herved og saet til anvendelse hertil.
DK0661328T3 (da) Hidtil ukendte epoxid-amin-addukter som hærdere til vandige epoxidsystemer
SU639535A1 (ru) Способ устранени деформации голени